Pharmacology of Nor-Ursodeoxycholic Acid (norUDCA)
NorUDCA is a side-chain-shortened derivative of ursodeoxycholic acid (UDCA) with unique pharmacological properties centered on cholehepatic shunting, which enables targeted bile duct delivery and hepatoprotective effects distinct from its parent compound.
Mechanism of Action
NorUDCA exhibits several key pharmacological characteristics that differentiate it from standard UDCA 1:
Resistance to amidation: Unlike UDCA, norUDCA is relatively resistant to conjugation with glycine or taurine, which enables its unique cholehepatic shunting mechanism 1, 2
Cholehepatic shunting: This property results in ductular targeting, bicarbonate-rich hypercholeresis, and direct cholangiocyte protection 1
Hepatic enrichment: Facilitates direct therapeutic effects on both parenchymal and non-parenchymal liver cells 1
Multiple therapeutic actions:
- Anti-cholestatic effects
- Anti-inflammatory properties
- Anti-fibrotic activity
- Anti-lipotoxic effects
- Inhibition of hepatocellular proliferation
- Promotion of autophagy 1
Immunomodulatory effects: Recent evidence demonstrates that norUDCA suppresses TH17 effector function, reduces TH17 pathogenicity, promotes transdifferentiation into regulatory T cells (Treg), and attenuates glutamine-mTORC1-glycolysis signaling in pathogenic TH17 cells 3
Pharmacokinetics
Based on the most recent phase I study 4:
- Absorption: Approximately 90% absorbed in the small bowel after oral administration (similar to UDCA) 5
- Tmax: 3-4 hours across dose ranges
- Half-life: 14-16 hours (dose-dependent, longer at higher doses)
- Dose proportionality: Cmax and AUC increase with dose from 500-1500 mg/day, though not strictly proportional
- Metabolism: Undergoes hepatic enrichment with minimal systemic circulation; resistant to conjugation compared to UDCA
Treatment Regimen
The recommended dosage of norUDCA is 1500 mg once daily, based on the most recent phase I safety data establishing this as the maximum tolerated dose and the phase III efficacy trial demonstrating optimal therapeutic benefit at this dose.
Dosing Recommendations
For Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Dose: 1500 mg once daily 6
- Duration: Minimum 12 weeks for initial response assessment; 24 weeks demonstrated sustained efficacy 6
- Efficacy at this dose:
- 89% achieved ALT normalization at week 12 (vs 76% placebo, P=0.022)
- 57% showed fibrosis improvement (vs 40% placebo, P=0.035)
- 90 patients showed liver stiffness improvement (vs 36 placebo, P=0.009)
For Non-Alcoholic Fatty Liver Disease (NAFLD)
- Dose: 1500 mg once daily 7
- Duration: 12 weeks minimum
- Efficacy: Mean 27.8% reduction in ALT (95% CI -34.7 to -14.4; P<0.0001) compared to placebo
For Primary Sclerosing Cholangitis (PSC)
While specific dosing is not detailed in the provided guidelines, norUDCA has been successfully tested clinically in PSC patients 1, representing its first clinical application.
Safety Profile
NorUDCA demonstrates excellent safety and tolerability across all studied doses 4, 6, 7:
- Maximum tolerated dose: 1500 mg/day with no dose-limiting toxicities observed 4
- Serious adverse events: None reported in phase I or phase III trials
- Common adverse events: Mild to moderate only
Clinical Monitoring
- Initial assessment: Baseline ALT, liver stiffness (FibroScan), NAFLD fibrosis score
- Week 12: Primary efficacy assessment (ALT normalization, fibrosis improvement)
- Week 18-24: Secondary assessments for sustained response
- Ongoing: Monitor liver enzymes, lipid profile, and glycosylated hemoglobin in metabolic disease patients 6
Important Caveats
- The 500 mg dose showed insufficient efficacy compared to 1500 mg in dose-finding studies 7
- NorUDCA is distinct from standard UDCA (which is dosed at 13-15 mg/kg/day for cholestatic diseases) and should not be substituted 8
- Current evidence supports use primarily in MASLD/NAFLD; applications in other cholestatic conditions are under investigation